Recruiting Studies
Advanced SearchData: ClinicalTrials.gov · Source of record for eligibility and locations
Top Cities for Tardive Dyskinesia Clinical Trials
Tardive Dyskinesia clinical trials are recruiting across 27 cities. Here are the cities with the most active studies:
Tardive Dyskinesia Trial Phases
7 research organizations are sponsoring tardive dyskinesia trials.
About Tardive Dyskinesia
Tardive dyskinesia is a neurological disorder characterized by involuntary, repetitive movements, especially of the face and tongue, caused by long-term use of certain psychiatric medications. It can be socially disabling and persistent. Treatment includes VMAT2 inhibitors (valbenazine, deutetrabenazine).
Clinical trials are advancing new treatments for tardive dyskinesia. Currently, 9 studies are recruiting a combined 2,424 participants across the United States. Research is being conducted by 7 organizations including University of Pennsylvania, Neurocrine Biosciences, Queen's Medical Center and 4 others.
2026 Tardive Dyskinesia Research Landscape
As of October 2026, the tardive dyskinesia clinical trial landscape includes 9 actively recruiting studies across 27 cities in the United States. These studies are collectively seeking 2,424 participants, with an average enrollment target of 269 per study.
The research spans multiple phases of development: 3 studies are in PHASE1, 2 studies are in PHASE4, 2 studies are in PHASE2, 1 study is in NA. Early-phase studies suggest new therapeutic approaches are being explored for tardive dyskinesia.
Research is being led by 7 different organizations, including University of Pennsylvania, Neurocrine Biosciences, Queen's Medical Center, Tessera Therapeutics, Inc., Uma Borate, and 2 others.
Geographically, tardive dyskinesia trials are most concentrated in Philadelphia, Pennsylvania (3 trials); Bryant, Arkansas (2 trials); Chino, California (2 trials); Long Beach, California (2 trials); Bonita Springs, Florida (2 trials) and 7 other cities.
Featured Tardive Dyskinesia Studies
Highlighted recruiting studies for tardive dyskinesia, selected by enrollment size and research scope.
UPenn Observational Research Repository on Neurodegenerative Disease
The aim of this study is to create a repository of both cross-sectional and longitudinal data, including cognitive, linguistic, imaging and biofluid biological specimens, for neurodegenerative disease research and treatment.
Biofluid Research on Age-Related or Inherited Neurodegeneration
The aim of this study is to contribute to and continue to sustain a repository of blood samples, nucleic acid (DNA and/or RNA) samples, family history information, and other demographic information from individuals with age-related neurodegenerative conditions, or their family members who may or may not be at risk for similar conditions. This study will continue to further expand research into the...
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
This study will evaluate the efficacy of valbenazine on clinician- and patient-reported outcomes in participants with TD while receiving or after stopping a VMAT2 inhibitor.
Frequently Asked Questions About Tardive Dyskinesia Clinical Trials
Are there tardive dyskinesia clinical trials near me?
Yes, there are 9 tardive dyskinesia clinical trials currently recruiting across 27+ cities in the United States, including Philadelphia, Pennsylvania; Bryant, Arkansas; Chino, California. Browse the studies above to find one at a location convenient for you.
How do I join a tardive dyskinesia clinical trial?
To join a tardive dyskinesia clinical trial: 1) Browse the available studies on this page, 2) Click on a study that interests you, 3) Check the study locations to find a site near you, 4) Review the eligibility criteria, and 5) Contact the study site or complete the eligibility form. The process is free and you can withdraw at any time.
Are tardive dyskinesia clinical trials free?
Yes, participation in tardive dyskinesia clinical trials is free. Study-related treatments, medical tests, and doctor visits are provided at no cost to participants. Many studies also offer compensation for your time and travel expenses.
What types of tardive dyskinesia treatments are being studied?
Current tardive dyskinesia clinical trials are testing a range of approaches across PHASE1 (3 studies), PHASE4 (2 studies), PHASE2 (2 studies), NA (1 study). These include new drugs, combination therapies, medical devices, and other interventions sponsored by 7 research organizations.
Is it safe to participate in tardive dyskinesia clinical trials?
Clinical trials are carefully regulated by the FDA and institutional review boards (IRBs). All trials must follow strict safety protocols, and participants receive close medical monitoring throughout the study. You can withdraw from a trial at any time without penalty.
Data updated October 15, 2026 from ClinicalTrials.gov
About This Data
Data: ClinicalTrials.gov · Source of record for eligibility and locations
Clinical trial information on this page is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health (NIH) and National Library of Medicine (NLM). Study data is refreshed every hour to ensure accuracy.
Medical Disclaimer: The information provided on this page is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before making decisions about clinical trial participation or changes to your treatment plan.
Page reviewed by the HelloStudys Research Team · Last updated October 15, 2026 · Data from ClinicalTrials.gov